Government-Owned Inventions; Availability for Licensing, 112-113 [E8-31238]
Download as PDF
<![CDATA[
112
Federal Register / Vol. 74, No. 1 / Friday, January 2, 2009 / Notices
benefit the workings of ACOT), and the
nominee’s field(s) of expertise; (2) a
biographical sketch of the nominee and
a copy of his/her curriculum vitae; and
(3) the name, return address, and
daytime telephone number at which the
nominator can be contacted.
The Department of Health and Human
Services has special interest in assuring
that women, minority groups, and the
physically disabled are adequately
represented on advisory committees;
and therefore, extends particular
encouragement to nominations for
appropriately qualified female,
minority, or disabled candidates.
Dated: December 21, 2008.
Elizabeth M. Duke,
Administrator, HRSA.
[FR Doc. E8–31219 Filed 12–31–08; 8:45 am]
BILLING CODE 4165–15–P
clinical research: Type of Information
Collection Request: New. Need and Use
of Information Collection: This study
National Institutes of Health
will assess the value of the training
programs administered by the Office of
Proposed Collection; Comment
Clinical Research Training and Medical
Request; the Impact of Clinical
Education. The primary objective of the
Research Training and Medical
survey is to determine if training
Education at the Clinical Center on
programs have had an impact on
Physician Careers in Academia and
whether the trainees are performing
Clinical Research
clinical research, hold an academic
appointment, have National Institutes of
SUMMARY: In compliance with the
Health funding sources as well as to
requirement of Section 3506(c)(2)(A) of
obtain information from the trainees as
the Paperwork Reduction Act of 1995,
to what part of the National Institutes of
for opportunity for public comment on
Health medical education program they
proposed data collection projects, the
feel could be improved upon, the
Clinical Center, the National Institutes
quality of the mentoring program, and
of Health will publish periodic
how their National Institutes of Health
summaries of proposed projects to be
training has contributed to their current
submitted to the Office of Management
clinical competence. Frequency of
and Budget for review and approval.
Proposed Collection: Title: The impact response: On occasion. Affected Public:
of clinical research training and medical Physicians, dentists, medical students,
dental students, nurses, and PhDs. The
education at the Clinical Center on
annual reporting burden is as follows:
physician careers in academia and
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Estimated
number
of responses
per respondent
Estimated
number
of respondents
Type of respondents
Average burden
hours per
response
Estimated total
annual burden
hours requested
625
100
100
1
1
1
0.5
0.5
0.5
312.5
50
50
Total ........................................................................................
mstockstill on PROD1PC66 with NOTICES
Doctoral Level ................................................................................
Students .........................................................................................
Nurses ............................................................................................
............................
............................
............................
362.5
There are no Capital Costs, Operating
Costs, and/or Maintenance Costs to
report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
the data collection plans and
instruments, contact Linda Wisniewski,
Nurse Consultant, Office of Clinical
Research Training and Medical
Education, CC, NIH, Building 10, Room
1N252B, 9000 Rockville Pike, Bethesda,
MD 20892 or 301–496–9425 or e-mail
your request, including your address to:
wisniewskil@cc.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: December 24, 2008.
Laura Lee,
Project Clearance Liaison, Warren Grant
Magnuson Clinical Center, National Institutes
of Health.
[FR Doc. E8–31240 Filed 12–31–08; 8:45 am]
BILLING CODE 4140–01–P
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
VerDate Aug<31>2005
16:23 Dec 31, 2008
Jkt 217001
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
E:\FR\FM\02JAN1.SGM
02JAN1
Federal Register / Vol. 74, No. 1 / Friday, January 2, 2009 / Notices
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
mstockstill on PROD1PC66 with NOTICES
Novel Inhibitor of NF-kappa B Pathway
Description of Technology: Many
tumors and blood cell cancers show
overactivation of the NF-kappa B signal
transduction pathway. This
overactivation is associated with cancer
forming in the colon, liver and other
epithelial sites. In addition, there is
evidence that overactivation leads to
tumor formation and metastasis.
However, this pathway is key for normal
immunity, so any inhibition of NFkappa B overactivation must avoid
diminishing the body’s ability to fight
infection.
This invention claims a compound
that inhibits NF-kappa B activation
without affecting other transcription
factors such as AP–1 and SRE binding
proteins. It appears to function by
blocking IKK beta and is effective at low
micromolar concentrations without
affecting cell proliferation or cell
survival. At this low concentration, NFkappa B is reduced to basal levels so
this novel compound has prospects for
preventing or treating cancer without
being detrimental to immunity. In
addition, because NF-kappa B
overactivation contributes to a variety of
inflammatory disorders including
colitis, diabetes, prostatitis, and
pancreatitis this compound has
therapeutic applications beyond cancer.
Applications:
• Therapeutic for the
chemoprevention or treatment of
cancers associated with the
overactivation of NF-kappa B signaling
pathway.
• Therapeutic for the treatment of
inflammatory disorders related to NFkappa B overactivation.
• Reagent for the diagnosis of
conditions related to overexpression of
NF-kappa B.
Advantages:
• Highly specific inhibitor that allows
targeting NF-kappa B without inhibiting
other transcription factors.
• Effective at preventing
carcinogenesis without affecting normal
cell proliferation and survival.
• Therapeutic for treatment of cancer
that will not compromise the immune
system.
Development Status: Early stage.
Market: Cancer is the second leading
cause of death in the U.S. and it is
estimated that 1.4 million Americans
develop cancer in a year.
VerDate Aug<31>2005
16:23 Dec 31, 2008
Jkt 217001
Inventors: Curtis J. Henrich et al.
(NCI).
Publications: None related to
invention have been published.
Patent Status: U.S. Provisional
Application No. 61/098,977 filed 22 Sep
2008 (HHS Reference No. E–295–2008/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Sabarni K.
Chatterjee, Ph.D.; 301–435–5587;
chatterjeesa@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute (SAICFrederick) is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize around development of
analogs and/or further investigations of
mechanism of action of the compound.
Please contact John D. Hewes, Ph.D. at
301–435–3121 or hewesj@mail.nih.gov
for more information.
Method for Predicting and Detecting
Tumor Metastasis
Description of Technology: Detecting
cancer prior to metastasis greatly
increases the efficacy of treatment and
the chances of patient survival.
Although numerous biomarkers have
been reported to identify aggressive
tumor types and predict prognosis, each
biomarker is specific for a particular
type of cancer, and no universal marker
that can predict metastasis in a number
of cancers have been identified. In
addition, due to a lack of reliability,
several markers are typically required to
determine the prognosis and course of
therapy.
The inventors discovered a novel CPE
splice variant designated CPE->N and
found its expression levels increase
according to the presence of cancer and
metastasis wherein this variant is
upregulated in tumors and further
increased in metastatic cancer. This data
has been demonstrated both in vitro and
in vivo experiments and in liver, breast,
prostate, colon, and head and neck
cancers. Metastatic liver cells treated
with CPE->N siRNA reversed the cells
from being metastatic and arrested cells
from further metastasis. Thus, this novel
CPE isoform is a biomarker for
predicting metastasis and its inhibitors
have an enormous potential to increase
patient survival.
Applications:
• Method to prognose multiple types
of cancer and determine likelihood of
metastasis.
• Method to prevent and treat cancer
with CPE inhibitors.
• Method to determine the stage of
cancer development.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
113
• CPE->N pharmaceutical
compositions.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Market:
• Global cancer market is worth more
than eight percent of total global
pharmaceutical sales.
• Cancer industry is predicted to
expand to $85.3 billion by 2010.
Inventors: Y. Peng Loh et al. (NICHD).
Patent Status: U.S. Provisional
Application No. 61/080,508 filed 14 Jul
2008 (HHS Reference No. E–234–2008/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Child Health
and Human Development, Laboratory of
Development Neurobiology, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize Method for Predicting
and Detecting Tumor Metastasis. Please
contact John D. Hewes, Ph.D. at 301–
435–3121 or hewesj@mail.nih.gov for
more information.
Dated: December 23, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–31238 Filed 12–31–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
E:\FR\FM\02JAN1.SGM
02JAN1
]]>Agencies
[Federal Register Volume 74, Number 1 (Friday, January 2, 2009)]
[Notices]
[Pages 112-113]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-31238]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive
[[Page 113]]
Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/
496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement
will be required to receive copies of the patent applications.
Novel Inhibitor of NF-kappa B Pathway
Description of Technology: Many tumors and blood cell cancers show
overactivation of the NF-kappa B signal transduction pathway. This
overactivation is associated with cancer forming in the colon, liver
and other epithelial sites. In addition, there is evidence that
overactivation leads to tumor formation and metastasis. However, this
pathway is key for normal immunity, so any inhibition of NF-kappa B
overactivation must avoid diminishing the body's ability to fight
infection.
This invention claims a compound that inhibits NF-kappa B
activation without affecting other transcription factors such as AP-1
and SRE binding proteins. It appears to function by blocking IKK beta
and is effective at low micromolar concentrations without affecting
cell proliferation or cell survival. At this low concentration, NF-
kappa B is reduced to basal levels so this novel compound has prospects
for preventing or treating cancer without being detrimental to
immunity. In addition, because NF-kappa B overactivation contributes to
a variety of inflammatory disorders including colitis, diabetes,
prostatitis, and pancreatitis this compound has therapeutic
applications beyond cancer.
Applications:
Therapeutic for the chemoprevention or treatment of
cancers associated with the overactivation of NF-kappa B signaling
pathway.
Therapeutic for the treatment of inflammatory disorders
related to NF-kappa B overactivation.
Reagent for the diagnosis of conditions related to
overexpression of NF-kappa B.
Advantages:
Highly specific inhibitor that allows targeting NF-kappa B
without inhibiting other transcription factors.
Effective at preventing carcinogenesis without affecting
normal cell proliferation and survival.
Therapeutic for treatment of cancer that will not
compromise the immune system.
Development Status: Early stage.
Market: Cancer is the second leading cause of death in the U.S. and
it is estimated that 1.4 million Americans develop cancer in a year.
Inventors: Curtis J. Henrich et al. (NCI).
Publications: None related to invention have been published.
Patent Status: U.S. Provisional Application No. 61/098,977 filed 22
Sep 2008 (HHS Reference No. E-295-2008/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Sabarni K. Chatterjee, Ph.D.; 301-435-5587;
chatterjeesa@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
(SAIC-Frederick) is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize around development of analogs and/or further
investigations of mechanism of action of the compound. Please contact
John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more
information.
Method for Predicting and Detecting Tumor Metastasis
Description of Technology: Detecting cancer prior to metastasis
greatly increases the efficacy of treatment and the chances of patient
survival. Although numerous biomarkers have been reported to identify
aggressive tumor types and predict prognosis, each biomarker is
specific for a particular type of cancer, and no universal marker that
can predict metastasis in a number of cancers have been identified. In
addition, due to a lack of reliability, several markers are typically
required to determine the prognosis and course of therapy.
The inventors discovered a novel CPE splice variant designated CPE-
[utri]N and found its expression levels increase according to the
presence of cancer and metastasis wherein this variant is upregulated
in tumors and further increased in metastatic cancer. This data has
been demonstrated both in vitro and in vivo experiments and in liver,
breast, prostate, colon, and head and neck cancers. Metastatic liver
cells treated with CPE-[utri]N siRNA reversed the cells from being
metastatic and arrested cells from further metastasis. Thus, this novel
CPE isoform is a biomarker for predicting metastasis and its inhibitors
have an enormous potential to increase patient survival.
Applications:
Method to prognose multiple types of cancer and determine
likelihood of metastasis.
Method to prevent and treat cancer with CPE inhibitors.
Method to determine the stage of cancer development.
CPE-[utri]N pharmaceutical compositions.
Development Status: The technology is currently in the pre-clinical
stage of development.
Market:
Global cancer market is worth more than eight percent of
total global pharmaceutical sales.
Cancer industry is predicted to expand to $85.3 billion by
2010.
Inventors: Y. Peng Loh et al. (NICHD).
Patent Status: U.S. Provisional Application No. 61/080,508 filed 14
Jul 2008 (HHS Reference No. E-234-2008/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301-435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of Child
Health and Human Development, Laboratory of Development Neurobiology,
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate, or
commercialize Method for Predicting and Detecting Tumor Metastasis.
Please contact John D. Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
Dated: December 23, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-31238 Filed 12-31-08; 8:45 am]
BILLING CODE 4140-01-P
